AI is reshaping drug discovery, with Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci advancing ...

Recursive’s $400 million outlay represents the bulk of the company’s fundraising to date.

Recursion Pharmaceuticals (NASDAQ:RXRX) is using artificial intelligence to generate and analyze biological data in an effort to improve drug discovery, advance internal therapeutic programs and ...

Recursion Pharmaceuticals' partnerships, notably with Genentech/Roche and Sanofi, have delivered $500M+ in milestone payments ...

Recursion, Roche, and its Genentech subsidiary have announced plans to co-develop a neuroscience discovery program based on ...

We are no longer just discussing the potential of our platform." (CEO, President & Director Najat Khan) "We now have 5 clinical stage programs, including REC-4881 in FAP, where we have generated some ...

The legendary Google executive is joined by other outgoing Google execs in a joint mission to use AI to push forward the ...

Genentech advanced the collaboration's first neuroscience target into a joint early discovery program, providing early ...

Recursive Self-Improvement in AI: From Bounded Self-Refinement to Autonomous Research Loops (July 2026) Unlimited ...

Jeff Dean, who for years was one of Google’s most important executives, is leading the new artificial intelligence company ...

OperaWire spoke with digital art and creative technologist Phil Hagen Jungschlaeger to learn more about what makes this production so special and unique.